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Background
Post translational modifications regulate several signal-
ling pathways and glycosylation is emerging as a key
player in this regulatory process. Glycosylation of cell sur-
face receptors modulate the downstream signalling path-
way and when altered causes a change in the normal
physiology of the cell [1]. Guanylyl cyclase C (GC-C)
belongs to a group of membrane bound receptors that
produce the second messenger, cGMP [2]. It is a multi-
domain protein in which the extracellular domain (ECD)
is N-glycosylated, resulting in the expression of two differ-
entially glycosylated forms of GC-C (130 kDa and 145
kDa) [3]. Apart from the endogenous peptide ligands gua-
nylin and uroguanylin, GC-C is activated by the heat sta-
ble enterotoxins (ST) produced by pathogenic Escherichia
coli [2]. It is only the 145 kDa form which is activated by
ST – a property attributed to the sugars present on it as
both forms bind the ligand with comparable affinities as
does the non-glycosylated ECD expressed in E. coli [4].
Infection with enteropathogenic E. coli hyperactivates GC-
C resulting in diseases such as infant mortality and travel-
lers' diarrhoea in adults. The glycosylation profile in the
infant intestine changes with time and diet which perhaps
leads to this differential response to ST in infants and
adults [5]. Glycosylation is also tissue specific, which may
result in differential regulation of GC-C present in extrain-
testinal tissues [6]. Altered glycosylation in cancer cells [7]
may also influence GC-C activity. Thus, this study aims to
understand the effect glycosylation has on GC-C function,
which may in turn influence cGMP production.
Results
Treatment of cells expressing GC-C with wheat germ
agglutinin resulted in inhibition of GC-C activity, while
treatment with Concanavalin A did not. This differential
response suggests that a specific lectin-sugar interaction
prevents receptor activation.
In order to determine the sites of glycosylation responsi-
ble for receptor activation, a mutational approach was
undertaken. The ten asparagine residues which are puta-
tive N-glycosylation sites in the ECD were mutated to
alanine. All mutant receptors showed ST-mediated cGMP
production in intact cells, but mutations at Asn345 and
Asn402 showed a 40% reduction in ST-stimulatability.
Western blot analysis of the single mutants showed differ-
ences in electrophoretic mobility between mutant and
wild type receptors, due to loss of glycosylation.
Conclusion
Apart from activation, glycosylation also protects proteins
from proteolytic cleavage. This is significant in the case of
GC-C given its localization in the intestinal lumen, where
proteolytic enzymes abound. The susceptibility of the
N345 mutant to tryptic cleavage revealed that glycosyla-
tion may be of physiological importance in the intestinal
milieu. Thus the varied roles of glycosylation in GC-C are
emerging and the specificity of these roles at different gly-
cosylation sites are being investigated.
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